Last week, our very own Mary Rosenzweig had the privilege of attending Bech-Bruun’s “Life Science Forum 2023 – the EU’s Revision of the Pharmaceutical Regulations” in Denmark. This event gathered prominent figures from the industry to discuss the first overhaul of the EU Pharmaceutical Legislation in two decades.
Central to the forum’s discussions were the effective incentives for innovation. Many participants concurred that a key challenge is managing the expectations of launching new medicines in all 27 EU member states within a 2-year window. The consensus was that achieving this is often complicated by local procedural timelines, independent of the manufacturer’s intent or actions at the time of launch.
This important space will continue to develop as the governments of member states, manufacturers, and industry associations continue to interact with the European Commission.
